



Discordances between pediatric and adult thresholds in the diagnosis of hypertension in adolescents with CKD

Elizabeth Black¹ · Jason Lee² · Joseph T. Flynn³ · Charles E. McCulloch⁴ · Joshua A. Samuels⁵ · Divya Seth⁶ · Bradley Warady⁷ · Susan Furth⁸ · Mark Mitsnefes⁹ · Elaine Ku^{1,4,6}

Received: 1 February 2021 / Revised: 24 May 2021 / Accepted: 2 June 2021 / Published online: 25 June 2021
© The Author(s) 2021

Abstract

Background Adolescents with chronic kidney disease (CKD) are a unique population with a high prevalence of hypertension. Management of hypertension during the transition from adolescence to adulthood can be challenging given differences in normative blood pressure values in adolescents compared with adults.

Methods In this retrospective analysis of the Chronic Kidney Disease in Children Cohort Study, we compared pediatric versus adult definitions of ambulatory- and clinic-diagnosed hypertension in their ability to discriminate risk for left ventricular hypertrophy (LVH) and kidney failure using logistic and Cox models, respectively.

Results Overall, among 363 adolescents included for study, the prevalence of systolic hypertension was 27%, 44%, 12%, and 9% based on pediatric ambulatory, adult ambulatory, pediatric clinic, and adult clinic definitions, respectively. All definitions of hypertension were statistically significantly associated with LVH except for the adult ambulatory definition. Presence of ambulatory hypertension was associated with 2.6 times higher odds of LVH using pediatric definitions (95% CI 1.4–5.1) compared to 1.4 times higher odds using adult definitions (95% CI 0.8–3.0). The c-statistics for discrimination of LVH was statistically significantly higher for the pediatric definition of ambulatory hypertension ($c=0.61$) compared to the adult ambulatory definition ($c=0.54$), and the Akaike Information Criterion was lower for the pediatric definition. All definitions were associated with progression to kidney failure.

Conclusion Overall, there was not a substantial difference in pediatric versus adult definitions of hypertension in predicting kidney outcomes, but there was slightly better risk discrimination of the risk of LVH with the pediatric definition of ambulatory hypertension.

Keywords Adolescents · Hypertension · Blood pressure · Chronic kidney disease

Dr Black and Dr Lee contributed equally as co-first authors. Dr Mitsnefes and Dr Ku contributed equally as co-senior authors.

✉ Elizabeth Black
elizabeth.black@ucsf.edu

¹ Division of Pediatric Nephrology, Department of Pediatrics, University of California San Francisco, 550 16th street, 5th Floor, San Francisco, CA 94158, USA

² Division of Pediatric Nephrology, Department of Pediatrics, University of Michigan, Ann Arbor, MI, USA

³ Division of Pediatric Nephrology, Department of Pediatrics, Seattle Children's Hospital, Seattle, WA, USA

⁴ Department of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, CA, USA

⁵ Division of Pediatric Nephrology, Department of Pediatrics, University of Texas, Houston, TX, USA

⁶ Division of Nephrology, Department of Medicine, University of California San Francisco, San Francisco, CA, USA

⁷ Division of Pediatric Nephrology, Department of Pediatrics, Children's Mercy Hospital, Kansas City, Missouri, USA

⁸ Division of Pediatric Nephrology, Department of Pediatrics, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA

⁹ Division of Pediatric Nephrology, Department of Pediatrics, Cincinnati Children's Hospital, Cincinnati, OH, USA

Introduction

In 2017, the American Academy of Pediatrics (AAP) released new clinical practice guidelines for the screening and management of pediatric patients with elevated blood pressure (BP) [1] that included updated definitions of hypertension in children and adolescents, including the adoption of an absolute clinic BP threshold to define hypertension in adolescents ≥ 13 years old in accordance with adult guidelines [2]. The introduction of these new definitions is likely to increase the prevalence of clinic-diagnosed hypertension in adolescent populations [3, 4], though the benefit of achieving lower BPs on the risk of left ventricular hypertrophy (LVH) and kidney failure is not as strongly supported by evidence based on the development of end-organ damage in younger adults. AAP guidelines for the interpretation of clinic and ambulatory BP readings in children currently rely on the use of normative data based on age, height, and sex. In contrast, adult guidelines have fixed thresholds for the definitions of hypertension that are independent of age, height, and sex [5]. Differences in the normative values used in adult and pediatric definitions of hypertension can lead to diagnostic confusion, particularly as patients transition from adolescence to adulthood, and normative values for children may be higher than the adult hypertension thresholds.

Children and adolescents with chronic kidney disease (CKD) are a unique population in whom these issues are even more important given the high prevalence of hypertension in this population and the role of hypertension in accelerating CKD progression [6]. Our objective in this study was to determine differences in the ability of pediatric versus adult definitions of ambulatory and clinic-diagnosed hypertension to discriminate clinical outcomes in an adolescent population with CKD. Outcomes of interest included LVH and onset of kidney failure. We hypothesized that using pediatric definitions of hypertension would result in better risk discrimination for the development of LVH and kidney failure when compared to use of adult definitions.

Methods

Study population

Details of the Chronic Kidney Disease in Children Cohort Study (CKiD) have been previously described [7]. Briefly, CKiD is an ongoing prospective multicenter cohort study of children between ages 1–16 years with estimated glomerular filtration rate (eGFR) between 30 and 90 mL/min/1.73 m² [7, 8] that aims to determine risk factors for progression of kidney disease and cardiovascular outcomes. CKiD participants were included in our analysis if they had echocardiogram, clinic BP, and ambulatory BP data at any visit where they were at least 13 years old. Of the

891 study participants, 246 were excluded due to age less than 13 years at the baseline or subsequent follow-up visits. An additional 282 individuals were excluded due to either missing echocardiogram (N = 72), ambulatory BP monitoring (N = 126), clinic BP (N = 17), or more than one of these elements (N = 67). A total of 363 adolescents with CKD met the criteria for inclusion in our analysis (Fig. 1).

The CKiD Study protocol has been reviewed by the Institutional Review Boards of each participating center. Informed consent was obtained from study participants across all CKiD sites. De-identified data were obtained from the NIDDK Central Repository. Data collection began October 2003 and were updated through July 2014. The University of California San Francisco Institutional Review Board considers this study not human subjects research. Data that support the findings of this study are available publicly through the National Institute of Diabetes and Digestive and Kidney Disease Central Repository (<https://www.niddkrepository.org/home/>).

Predictors of interest

We focused primarily on systolic blood pressure (SBP) to define hypertension and examined its association with adverse outcomes throughout this study given that diastolic norms change minimally with height and age in adolescents [1, 9].




Fig. 1 Flow chart of inclusion of patients in study

Additionally, prior studies have demonstrated the greater prognostic importance of SBPs, as opposed to diastolic blood pressures (DBPs) in their association with LVH [10–12] and kidney failure [13] in children with CKD. However, we also examined DBP in separate analyses.

Ambulatory blood pressure monitoring

Ambulatory BP monitoring was performed during the CKiD Study using a SpaceLabs 90217 monitor (SpaceLabs Healthcare, WA), with BPs taken every 20 min over 24h and centrally analyzed as described previously [12, 14]. Ambulatory BP monitoring was performed at baseline and during follow-up visits (and typically on the same day as the research echocardiogram) every 2 years. We evaluated awake or sleep ambulatory BP readings separately as in prior CKiD studies [11, 14–17].

Clinic blood pressure

All clinic-based BPs were performed on the mid-upper arm by trained and certified personnel by auscultation during the CKiD Study annually using an aneroid sphygmomanometer with an appropriate cuff size [1]. Recertification of personnel obtaining BPs and calibration of the aneroid device occurred annually. Three consecutive seated readings were obtained at each study visit 30 s apart after at least 5 min of quiet rest, and the average of these three readings was considered the clinic BP for that visit. The clinic BP from the visit closest in time to ambulatory BP monitoring performance (median time difference between clinic BP and 24-h ambulatory BP monitoring was 0 days; interquartile range, 0–1 days) was used as one of the predictors of interest. This approach is consistent with the methods used in prior CKiD studies [17].

Hypertension definitions

We generated dichotomous predictors from both pediatric and adult ambulatory and clinic BP guidelines to define the presence of systolic hypertension and evaluated the strength of the association between pediatric clinic and pediatric ambulatory and adult clinic and adult ambulatory hypertension with each outcome of interest in separate models.

We defined pediatric ambulatory systolic hypertension using SBP norms based on sex and height as in prior CKiD studies [9, 12, 17] and considered an awake SBP \geq the 95th percentile for sex and height or asleep SBP \geq the 95th percentile for sex and height to meet the definition of pediatric ambulatory hypertension. We defined adult ambulatory systolic hypertension using systolic BP thresholds from the AHA guidelines (mean awake systolic BP \geq 130 mmHg or mean sleep SBP \geq 110 mmHg) [2]. Next, we defined pediatric clinic systolic hypertension as a SBP \geq 95th percentile for age, sex,

and height as per guidelines published in 2004 but used updated normative tables from AAP 2017 guidelines to ensure contemporary relevance of this definition [18]. For pediatric clinic systolic hypertension, we did not incorporate any adult definitions of hypertension as per prior 2004 AAP guidelines. Adult clinic systolic hypertension was defined as SBP \geq 130 mmHg [2].

In sensitivity analysis, to address new changes in the 2017 pediatric clinical practice guidelines where adult thresholds are incorporated into the definition of hypertension for those \geq 13 but $<$ 18 years of age, we separately defined hypertension using a composite hypertension definition that incorporated either pediatric or adult thresholds. Specifically, the composite ambulatory systolic hypertension definition was defined as awake or sleep SBP \geq 95th percentile for sex and height or awake SBP \geq 130 mmHg or sleep SBP \geq 110 mmHg by ABPM, whichever is lower. The composite clinic systolic hypertension definition was expanded to include either clinic SBP \geq 95th percentile for age, sex, and height or SBP \geq 130mmHg, whichever is lower. See Table 1 for a summary of all hypertension definitions used in this analysis.

For diastolic hypertension, we defined pediatric ambulatory diastolic hypertension using DBP and considered an awake DBP \geq the 95th percentile for sex and height or asleep DBP \geq the 95th percentile for sex and height to meet the definition of pediatric ambulatory diastolic hypertension. We defined adult ambulatory diastolic hypertension using DBP thresholds from the AHA guidelines (mean awake DBP \geq 80 mmHg or mean sleep DBP \geq 65 mmHg). Next, we defined pediatric clinic diastolic hypertension as a DBP \geq 95th percentile for age, sex, and height and adult clinic diastolic hypertension as DBP \geq 80 mmHg. In sensitivity analysis, we defined composite ambulatory diastolic hypertension as awake or sleep DBP \geq 95th percentile for sex and height or awake DBP \geq 80 mmHg or sleep DBP \geq 65 mmHg. Composite clinic diastolic hypertension was defined as either DBP \geq 95th percentile for age, sex, and height or DBP \geq 80 mmHg.

Outcomes of interest

Left ventricular hypertrophy

Echocardiograms and 24-h ambulatory BP monitoring were performed every 2 years after the baseline visit. M-mode and Doppler echocardiograms were performed by trained technologists at each CKiD site using a standardized protocol [12]. We defined LVH using the same definitions used in prior CKiD studies, which is a left ventricular mass index \geq 95th percentile for children and adolescents [12]. The median time difference between 24-h ambulatory BP monitoring and echocardiogram performance was 0 days (interquartile range -1 to 1 days). Our primary analysis of LVH was based on the echocardiogram performed at baseline enrollment or at the first

Table 1 Blood pressure definitions

BP metrics	Definition
Systolic hypertension	
Pediatric ambulatory systolic threshold	Awake or sleep systolic BP \geq 95th percentile for sex and height
Pediatric clinic systolic threshold	Systolic BP \geq 95th percentile for age, sex, and height
Adult ambulatory systolic threshold	Awake systolic BP of \geq 130 mmHg or sleep systolic BP \geq 110 mmHg
Adult clinic systolic threshold	Systolic BP \geq 130 mmHg
Composite ambulatory threshold	Awake or sleep systolic BP \geq 95th percentile for sex and height or awake systolic BP \geq 130 mmHg or sleep systolic BP \geq 110 mmHg, whichever is lower
Composite clinic threshold	Systolic BP \geq 130 mmHg or \geq 95th percentile for age, whichever is lower
Diastolic hypertension	
Pediatric ambulatory diastolic threshold	Awake or sleep diastolic BP \geq 95th percentile for sex and height
Pediatric clinic diastolic threshold	Diastolic BP \geq 95th percentile for age, sex, and height
Adult ambulatory diastolic threshold	Awake diastolic BP of \geq 80 mmHg or sleep diastolic BP \geq 65 mmHg
Adult clinic diastolic threshold	Diastolic BP \geq 80 mmHg
Composite ambulatory diastolic threshold	Awake or sleep diastolic BP \geq 95th percentile for sex and height or awake diastolic BP \geq 80 mmHg or sleep diastolic BP \geq 65 mmHg, whichever is lower
Composite clinic diastolic threshold	Diastolic BP \geq 80 mmHg or \geq 95th percentile for age, whichever is lower

BP blood pressure

qualifying study visit where participants were \geq 13 years of age.

Long-term kidney failure ascertainment

Ascertainment of kidney failure onset (defined as the first date of dialysis or transplantation) was performed at annual CKiD visits, by phone follow-up, or by the provision of data from providers. Patients were administratively censored if they were alive as of July 2014 and had not yet developed kidney failure or if they were lost to follow-up at time of the last known study visit.

Statistical analysis

Hypertension and its association with outcomes

First, we used either ambulatory or clinic BP readings to categorize the BP status of each adolescent in the cohort as hypertensive or normotensive by systolic and diastolic definitions and reported the prevalence of HTN according to each of the definitions described above. We compared the baseline characteristics of individuals who were hypertensive by each of these definitions.

Next, we examined the association between BP status (hypertensive or not) based on each of the definitions and LVH using logistic models (cross-sectional analysis) and kidney failure in Cox models (longitudinal analysis) in unadjusted and adjusted analyses. For longitudinal kidney failure analyses, time-to-event was determined starting from the date of the visit when the participant was first \geq 13 years and had ABPM data available [19]. We considered our primary models unadjusted analyses, since our statistical analysis focuses on the comparison of guideline-recommended definitions of hypertension in their association with outcomes, and in routine clinical practice, other factors are not simultaneously considered when managing hypertension. However, in secondary analysis, we also performed adjusted analysis and accounted for age, sex, race (white, black, or other), body mass index, urine protein-to-creatinine ratio, and estimated glomerular filtration rate as covariates. Results of the adjusted analyses are available in the supplementary materials.

In the sensitivity analysis, we repeated our analyses using the composite ambulatory and clinic hypertension definitions.

Risk discrimination using different hypertension definitions

To provide formal tests of the ability of each BP definition to discriminate risk of outcomes, c-statistics were determined for

each logistic or Cox model. In logistic models, the c-statistics were determined as the area under the receiver operator curve. In Cox models, Harrell's c-statistics were used. C-statistics, or concordance statistics, provide a measure of risk discrimination (i.e., the probability that a person with the event has a higher predicted probability than a person without the event). Confidence intervals for c-statistics (to evaluate the discrimination of each Cox model) and their differences (to compare discrimination) were determined via bootstrapping technique (using 500 repetitions). We additionally compared our models using Akaike Information Criterion (AIC). AIC is a numerical expression of the amount of information provided by a model, with a lower number indicating a better fit. An AIC difference of 10 or more is generally considered a significant difference [20]. We repeated our models in adjusted analyses, accounting for the same covariates as described above and determined the c-statistics and AIC for these adjusted models.

Stata 14 (StataCorp, TX: LLC) was used for the performance of all statistical analyses and verified by a separate analyst. P-values <0.05 were considered statistically significant for all analyses.

Results

Among the 363 adolescents included in this analysis (Fig. 1), the median age was 15.5 years, and 15.2% were black (Table 2). The mean follow-up time was 2.8 years. The prevalence of systolic hypertension was 27%, 12%, 44%, and 9% based on pediatric ambulatory and clinic and adult ambulatory and clinic definitions, respectively. In sensitivity analysis, the prevalence of systolic hypertension was 45% by the composite ambulatory definition and 12% by the composite clinic definition (Fig. 2). The prevalence of diastolic hypertension was 26%, 17%, 31%, and 16% based on pediatric ambulatory and clinic and adult ambulatory and clinic definitions, respectively. In sensitivity analysis, the presence of diastolic hypertension was 31% by the composite ambulatory definition and 18% by the composite clinic definition (Supplemental Figure 1). The characteristics of the overall cohort and those who were found to be hypertensive by each definition are shown in Table 2 for systolic hypertension and Supplemental Table 1 for diastolic hypertension. With regard to the outcomes of interest, 12% of the cohort had LVH, and 24% developed kidney failure over mean follow-up of 2.8 years.

The prevalence of masked hypertension was 19% by pediatric systolic hypertension definitions and 35% by adult systolic definitions. The prevalence of white coat hypertension was 3% by pediatric systolic definitions and < 1% by adult systolic definitions. The prevalence of daytime systolic hypertension was 20%, and nocturnal systolic hypertension was 20% by pediatric ambulatory definitions. The prevalence of

daytime systolic hypertension was 22%, and nocturnal systolic hypertension was 41% by adult ambulatory definitions.

All definitions of clinic or ambulatory systolic hypertension were statistically significantly associated with odds of LVH except for the adult ambulatory and composite hypertension definitions (Table 3) in unadjusted models. The c-statistic for discrimination of LVH was low across all systolic definitions but statistically significantly higher for the pediatric definition of ambulatory systolic hypertension ($c = 0.61$) compared to the adult ambulatory systolic definition ($c = 0.54$) and the composite ambulatory systolic definition ($c = 0.56$). In sensitivity analysis, we found that the pediatric definition of ambulatory systolic hypertension also had the lowest AIC compared to all other models, though the difference was not large across all definitions of hypertension. There was no statistically significant difference in discrimination for LVH by either the pediatric or adult definitions of clinic systolic hypertension compared to the reference group (Table 3 and Supplemental Table 2).

In unadjusted analysis, the point estimate for the strength of the association between the pediatric ambulatory definition of systolic hypertension and kidney failure was qualitatively not as strong compared to all other definitions, though all definitions were statistically significantly associated with kidney failure. The c-statistic for kidney failure was low across all definitions of systolic or diastolic hypertension using clinic or ambulatory measurements (Table 4 and Supplemental Table 3). There was no statistically significant difference in risk discrimination by c-statistic between any of the definitions of hypertension in unadjusted analysis, but the AIC was lowest for the composite clinic definition when compared to all other definitions of systolic hypertension.

With regard to diastolic hypertension, none of the definitions were statistically associated with the outcome of LVH in unadjusted analyses (Supplemental Table 4). Risk discrimination and model fit were similar across all definitions of diastolic hypertension. All definitions of diastolic hypertension were statistically associated with kidney failure, though the c-statistics and AICs were very similar across all definitions (Supplemental Table 5).

Discussion

In this study of adolescents with CKD, a higher prevalence of hypertension was noted when using 24-h ambulatory monitoring compared to clinic measurements of hypertension. Our data are consistent with prior studies which have shown a prevalence of masked hypertension of 10–38% in children with CKD and reinforces the utility of ABPM in the adolescent CKD population [6, 12, 21, 22].

Overall, we found that the adult clinic definitions of systolic hypertension had the strongest point estimate in terms of its

Table 2 Baseline characteristics of study by systolic hypertension participants

Characteristic	Pediatric			Adult			Composite		
	Overall	Hypertensive by ambulatory systolic threshold	Hypertensive by pediatric clinic systolic threshold	Hypertensive by ambulatory systolic threshold	Hypertensive by pediatric clinic systolic threshold	Hypertensive by adult clinic systolic threshold	Hypertensive by ambulatory systolic threshold	Hypertensive by pediatric clinic systolic threshold	Hypertensive by composite clinic systolic threshold
	N=363	N=99	N=40	N=160	N=32	N=166	N=43		
Median age (IQR) in years	15.5 [14.0–17.0]	16.0 [14.0–17.1]	16.0 [14.0–17.1]	16.0 [14.3–17.1]	17.0 [15.0–17.7]	16.0 [14.1–17.1]	16.0 [14.0–17.1]		
Female (%)	41.0	44.4	42.5	29.3	37.5	31.3	39.5		
Black (%)	15.2	20.2	22.5	19.4	21.9	19.3	20.9		
Glomerular cause of CKD (%)	33.1	30.3	30.0	31.3	40.6	30.7	32.6		
Use of at least one antihypertensive (%)	72.5	72.7	77.5	68.1	75.0	68.1	76.7		
Median eGFR mL/1.73m ² /minute by Schwartz equation (IQR)	46.6 [29.3–59.8]	38.2 [27.2–56.2]	29.2 [18.5–50.9]	42.5 [25.1–57.4]	32.2 [18.9–53.0]	42.8 [26.2–58.2]	28.9 [18.2–49.7]		
Median BMI z-score (IQR)	0.38 [–0.34 to 1.34]	0.30 [–0.50 to 1.22]	0.58 [–0.11 to 1.73]	0.28 [–0.48 to 1.25]	0.78 [0.01–1.86]	0.29 [–0.45 to 1.34]	0.53 [–0.11 to 1.73]		
Presence of LVH (%)	11.9	20.2	22.5	13.8	25.0	14.5	20.9		
Progression to kidney failure (%)	23.7	30.3	47.5	28.8	46.9	28.3	48.8		

CKD chronic kidney disease, eGFR estimated glomerular filtration rate, LVH left ventricular hypertrophy, BMI body mass index




Fig. 2 Prevalence of systolic hypertension

association with LVH in unadjusted analysis, which might have been expected given that the adult SBP threshold of ≥ 130 mmHg used to define hypertension is higher than the 95th percentile of normative values for most adolescents except those who are very tall or close to 18 years in age. In our primary (unadjusted) analysis, we found that the pediatric ambulatory threshold provided better risk discrimination for the outcome of LVH than either the adult or composite ambulatory definitions of hypertension which incorporated pediatric and adult definitions [1]. These findings may reflect challenges in accurately predicting LVH in children, given that the absolute risk discrimination remained low across all definitions, although the pediatric ambulatory definition of hypertension performed better than all other definitions. These findings deserve replication and validation in other cohorts of adolescents with CKD.

For the outcome of kidney failure, in unadjusted analysis, most definitions of systolic hypertension and all definitions of diastolic hypertension were statistically significantly associated with the risk of kidney failure. We did not find any statistically significant differences in risk discrimination provided

by any of the definitions of hypertension, although generally clinic-based definitions of hypertension were more strongly associated with kidney failure than ambulatory definitions in unadjusted analysis. The AIC for the composite clinic definition of systolic hypertension was lowest compared to all other definitions. A European randomized control trial previously demonstrated the benefit of intensively lowering mean ambulatory BP to the < 50 th percentile for retarding the progression of CKD in children [23, 24]. This benefit is less clear in adults [25, 26] in whom stricter blood pressure control was not found to retard progression of CKD except in those with proteinuria [27] but has been found to reduce the risk of cardiovascular events and mortality [28]. It is important to note that adult trials testing alternative BP targets have mostly enrolled older adults, though a few studies have now specifically examined the young adult age group. One study of younger adults aged 20–40 years in South Korea did find a higher risk of cardiovascular disease outcomes, including myocardial infarction, stroke, and heart failure, among patients with moderate elevations in BP (SBP 120–129, DBP < 80 mmHg) and in those with hypertension [29]. This finding was contradicted by a

Table 3 Association between different definitions of systolic hypertension and left ventricular hypertrophy (in cross-section) in unadjusted analysis along with model discrimination in adolescents with CKD.

BP metrics N=363	Pediatric		Adult		Composite	
	Pediatric ambulatory systolic threshold	Pediatric clinic systolic threshold	Adult ambulatory systolic threshold	Adult clinic systolic threshold	Composite ambulatory systolic threshold	Composite clinic systolic threshold
Unadjusted OR (95% CI)	2.6 (1.4–5.1)	2.5 (1.1–5.4)	1.4 (0.7–2.6)	2.8 (1.2–6.8)	1.6 (0.8–3.0)	1.2 (0.9–5.0)
Unadjusted c-statistic (95% CI)	0.61 (0.53–0.69) ^a	0.56 (0.49–0.62)	0.54 (0.46–0.62)*	0.56 (0.49–0.62)	0.56 (0.53–0.69)*	0.55 (0.49–0.61)
Unadjusted AIC	259.8 ^b	264.0	267.1	263.4	266.2	264.8
Unadjusted Δ_{AIC} ^c	Reference	4.2	7.3	3.6	6.4	5.0

^a Reference group for c-statistic comparisons

^b Reference group of AIC comparisons

^c Δ_{AIC} is the difference in AIC score between the definition of interest and the reference group

*C-statistic was statistically significantly lower compared to reference definition of hypertension

AIC Akaike Information Criterion

Table 4 Association between different definitions of hypertension and kidney failure in unadjusted analysis along with model discrimination in adolescents with CKD.

BP metrics N=363	Pediatric		Adult		Composite	
	Pediatric ambulatory systolic threshold	Pediatric clinic systolic threshold	Adult ambulatory systolic threshold	Adult clinic systolic threshold	Composite ambulatory systolic threshold	Composite clinic systolic threshold
Unadjusted HR (95% CI)	1.7 (1.1–2.6)	2.8 (1.7–4.7)	2.2 (1.4–3.3)	2.4 (1.4–4.2)	2.0 (1.3–3.0)	2.9 (1.8–4.8)
Unadjusted c-statistic 95% CI	0.55 (0.49–0.61) ^a Reference	0.57 (0.53–0.62)	0.56 (0.50–0.62)	0.56 (0.51–0.60)	0.56 (0.50–0.62)	0.58 (0.53–0.63)
Unadjusted AIC	881.3 ^b	873.0	873.9	878.1	876.4	871.3
Unadjusted Δ_{AIC} ^c	Reference	-8.3	-7.4	-3.2	-4.9	-10.0

^a Reference group for c-statistic comparisons

^b Reference group of AIC comparisons

^c Δ_{AIC} is the difference in AIC score between the reference and the AIC score being compared

AIC Akaike Information Criterion

recent study of patients with CKD aged 21–40 which found no significant difference in the risk of end-organ damage between participants with normal blood pressure and those with moderate elevations in BP (SBP 120–129) [30]. Thus, the applicability of these findings in adolescents remains uncertain.

To our knowledge, no trial data are available to robustly support the appropriate BP targets in the young adult population. Several observational studies have found an increase in the risk of premature death among patients with hypertension in adolescence and young adulthood [31, 32], but the generalizability of these findings to adolescents and young adults with CKD is unclear. One large study of Swedish men found a U-shaped relationship between systolic blood pressure in late adolescence and mortality, with the lowest risk being at 130 mmHg, suggesting that overly aggressive blood pressure control could be associated with harm [33]. Additionally, the risks of long-term antihypertensive therapy over many decades are unknown, since most adults do not begin antihypertensive therapy until middle or older age. Some studies have suggested, for example, that that long-term use of both diuretics [34–37] and beta blockers [38–40] increase the future risk of development of diabetes. Hence, the threshold used to define hypertension in an adolescent or young adult population is important given the need to balance potential side effects of antihypertensive medication with the detrimental effects of elevated blood pressure.

As adolescents with CKD transition into adult healthcare systems, the optimal approach to the diagnosis of hypertension remains unclear. The 2017 AAP guideline chose clinic BP thresholds for adolescents that corresponded to new adult thresholds in order to simplify the identification of

hypertension in adolescents and facilitate transition of care. While the 2016 European Society of Hypertension pediatric clinical practice guidelines do recommend adoption of adult ambulatory BP thresholds for older adolescents [41], the current AAP guidelines do not include this recommendation [42]. Additionally, the 2016 European Society of Hypertension clinical practice guidelines use higher thresholds for the diagnosis of adult ambulatory hypertension than the American Heart Association, making comparisons between European and American ambulatory blood pressure data difficult to interpret. Based on our data, using the height-based thresholds for ambulatory systolic hypertension may be acceptable in the adolescent CKD population as it provides modestly better discrimination for LVH when compared to adult and composite definitions of ambulatory hypertension, although the absolute risk discrimination for LVH was overall low.

The strengths of our study include the availability of research-grade clinic and ambulatory BP data from a well-described cohort of children with CKD followed closely for more than a decade with close monitoring for outcomes such as kidney failure and LVH. Limitations include the use of normative pediatric data for ambulatory BP derived from a homogenous European population which may have limited application to the ethnically and racially diverse CKiD cohort. Additionally, only patients with CKD were included in this study, and our findings, including the prevalence of masked and white coat hypertension, may not be applicable to healthy adolescents or adolescents with other chronic conditions. Our study also does not directly address the use of antihypertensive medications, medication adherence, or medication administration timing.

Conclusion

Hypertension is a common comorbidity in adolescents with CKD. However, it is unclear whether clinicians should use adult or pediatric definitions of hypertension in patients with CKD in this transitional age group. Our findings suggest that the use of pediatric ambulatory definitions of hypertension may be acceptable as these definitions of systolic hypertension had modestly better discrimination for the outcome of LVH among adolescents aged 13 years and older with CKD, although risk discrimination was overall low across all definitions of hypertension. There was no clear difference in predictive ability between adult or pediatric definitions of systolic or diastolic hypertension in terms of the ability to predict kidney outcomes, suggesting that use of either may be acceptable during the transition of care from a kidney perspective. Further confirmation of our findings in other cohorts of children with CKD is needed, and trials testing alternative BP targets in the young adult CKD population are warranted to better inform clinical care of younger populations.

Supplementary Information The online version contains supplementary material available at <https://doi.org/10.1007/s00467-021-05166-w>.

Acknowledgements The Chronic Kidney Disease in Children Cohort Study (CKiD) was conducted by the CKiD Investigators and supported by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), with additional funding from the National Institute of Child Health and Human Development and the National Heart, Lung, and Blood Institute (U01-DK-66143, U01-DK-66174, U01DK-082194, U01-DK-66116). The data and samples from the CKiD study reported here were supplied by the NIDDK Central Repositories.

The authors would like to acknowledge Dr. Barbara Grimes for her review of the statistical code used in this analysis.

Dr. Black was supported by a National Institute of Diabetes and Digestive and Kidney Disease Institutional Research Training Grant (NIDDK 5T32DK007219-44).

Author contribution Dr. Black and Dr. Lee conceptualized and designed the study, performed data analysis, drafted the initial manuscript, and reviewed and revised the manuscript; Dr. McCulloch assisted data analysis and critically reviewed the manuscript for important intellectual content; Ms. Seth assisted with study design and reviewed and revised the manuscript; Dr. Warady and Dr. Furth helped conceptualize the study and reviewed and revised the manuscript for important intellectual content; Dr. Flynn, Dr. Samuels, Dr. Mitsnefes, and Dr. Ku oversaw study design, assisted with data analysis, and critically reviewed the manuscript for important intellectual content. All authors approved the final manuscript as submitted and agree to be accountable for all aspects of the work. We thank Dr. Barbara Grimes for reviewing the statistical analysis.

Funding This work was supported by the National Institutes of Health (K23 HL131023 to Dr. Ku). The National Institutes of Health had no role in study design; the collection, analysis, and interpretation of data; the writing of the report; or the decision to submit the paper for publication.

Availability of data and material The data used in this research are available through the National Institute of Diabetes and Digestive and Kidney Disease Central Repository (<https://www.niddkrepository.org/home/>).

Code availability Statistical analysis was performed using Stata 14 (StataCorp, TX: LLC).

Declarations

Conflict of interest The authors declare no competing interests.

Disclaimer This manuscript does not necessarily reflect the opinions or views of the CKiD study, the NIDDK Central Repositories, or the NIDDK.

References

1. Flynn JT, Kaelber DC, Baker-Smith CM, Blowey D, Carroll AE, Daniels SR, de Ferranti SD, Dionne JM, Falkner B, Flinn SK, Gidding SS, Goodwin C, Leu MG, Powers ME, Rea C, Samuels J, Simasek M, Thaker VV, Urbina EM (2017) Clinical practice guideline for screening and management of high blood pressure in children and adolescents. *Pediatrics* 140:e20171904
2. Whelton PK, Carey RM, Aronow WS, Casey DE Jr, Collins KJ, Dennison Himmelfarb C, DePalma SM, Gidding S, Jamerson KA, Jones DW, MacLaughlin EJ, Muntner P, Ovbigele B, Smith SC Jr, Spencer CC, Stafford RS, Taler SJ, Thomas RJ, Williams KA Sr, Williamson JD, Wright JT Jr (2018) 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association Task Force on clinical practice guidelines. *Circulation* 138:e484–e594
3. Khoury M, Khoury PR, Dolan LM, Kimball TR, Urbina EM (2018) Clinical implications of the revised AAP pediatric hypertension guidelines. *Pediatrics* 142:e20180245
4. Blanchette E, Flynn JT (2019) Implications of the 2017 AAP clinical practice guidelines for management of hypertension in children and adolescents: a review. *Curr Hypertens Rep* 21:35
5. Flynn JT, Daniels SR, Hayman LL, Maahs DM, McCrindle BW, Mitsnefes M, Zachariah JP, Urbina EM (2014) Update: ambulatory blood pressure monitoring in children and adolescents: a scientific statement from the American Heart Association. *Hypertension* 63: 1116–1135
6. Wilson AC, Flynn JT (2020) Blood pressure in children with chronic kidney disease: lessons learned from the chronic kidney disease in children cohort study. *Pediatr Nephrol* 35:1203–1209. <https://doi.org/10.1007/s00467-019-04288-6>
7. Furth SL, Cole SR, Moxey-Mims M, Kaskel F, Mak R, Schwartz G, Wong C, Munoz A, Warady BA (2006) Design and methods of the chronic kidney disease in children (CKiD) prospective cohort study. *Clin J Am Soc Nephrol* 1:1006–1015
8. Wong CJ, Moxey-Mims M, Jerry-Flucker J, Warady BA, Furth SL (2012) CKiD (CKD in children) prospective cohort study: a review of current findings. *Am J Kidney Dis* 60:1002–1011
9. Soergel M, Kirschstein M, Busch C, Danne T, Gellermann J, Holl R, Krull F, Reichert H, Reusz GS, Rascher W (1997) Oscillometric twenty-four-hour ambulatory blood pressure values in healthy children and adolescents: a multicenter trial including 1141 subjects. *J Pediatr* 130:178–184

10. Sorof JM, Cardwell G, Franco K, Portman RJ (2002) Ambulatory blood pressure and left ventricular mass index in hypertensive children. *Hypertension* 39:903–908
11. Kupferman JC, Aronson Friedman L, Cox C, Flynn J, Furth S, Warady B, Mitsnefes M (2014) BP control and left ventricular hypertrophy regression in children with CKD. *J Am Soc Nephrol* 25:167–174
12. Mitsnefes M, Flynn J, Cohn S, Samuels J, Blydt-Hansen T, Saland J, Kimball T, Furth S, Warady B, CKiD Study Group (2010) Masked hypertension associates with left ventricular hypertrophy in children with CKD. *J Am Soc Nephrol* 21:137–144
13. Warady BA, Abraham AG, Schwartz GJ, Wong CS, Munoz A, Betoko A, Mitsnefes M, Kaskel F, Greenbaum LA, Mak RH, Flynn J, Moxey-Mims MM, Furth S (2015) Predictors of rapid progression of glomerular and nonglomerular kidney disease in children and adolescents: the chronic kidney disease in children (CKiD) cohort. *Am J Kidney Dis* 65:878–888
14. Samuels J, Ng D, Flynn JT, Mitsnefes M, Poffenbarger T, Warady BA, Furth S (2012) Ambulatory blood pressure patterns in children with chronic kidney disease. *Hypertension* 60:43–50
15. Barletta G-M, Flynn J, Mitsnefes M, Samuels J, Friedman LA, Ng D, Cox C, Poffenbarger T, Warady B, Furth S (2014) Heart rate and blood pressure variability in children with chronic kidney disease: a report from the CKiD study. *Pediatr Nephrol* 29:1059–1065
16. Mitsnefes MM, Pierce C, Flynn J, Samuels J, Dionne J, Furth S, Warady B, CKiD Study Group (2016) Can office blood pressure readings predict masked hypertension? *Pediatr Nephrol* 31:163–166
17. Ku E, McCulloch CE, Warady BA, Furth SL, Grimes BA, Mitsnefes MM (2018) Twenty-four-hour ambulatory blood pressure versus clinic blood pressure measurements and risk of adverse outcomes in children with CKD. *Clin J Am Soc Nephrol* 13:422–428
18. National High Blood Pressure Education Program Working Group on High Blood Pressure in Children and Adolescents (2004) The fourth report on the diagnosis, evaluation, and treatment of high blood pressure in children and adolescents. *Pediatrics* 114(2 Suppl 4th Report):555–576
19. Pencina MJ, D'Agostino RB Sr (2015) Evaluating discrimination of risk prediction models: the c statistic. *JAMA* 314:1063–1064
20. Portet S (2020) A primer on model selection using the Akaike Information Criterion. *Infect Dis Model* 5:111–128
21. Stergiou GS, Yiannes NJ, Rarra VC, Alamara CV (2005) White-coat hypertension and masked hypertension in children. *Blood Press Monit* 10:297–300
22. Gupta D, Chaturvedi S, Chandy S, Agarwal I (2015) Role of 24-h ambulatory blood pressure monitoring in children with chronic kidney disease. *Indian J Nephrol* 25:355
23. Siragy HM (2010) ESCAPE: from hypertension to renal failure. *Curr Hypertens Rep* 12:207–209
24. ESCAPE Trial Group (2009) Strict blood-pressure control and progression of renal failure in children. *N Engl J Med* 361:1639–1650
25. Appel LJ, Wright JT Jr, Greene T, Agodoa LY, Astor BC, Bakris GL, Cleveland WH, Charleston J, Contreras G, Faulkner ML (2010) Intensive blood-pressure control in hypertensive chronic kidney disease. *N Engl J Med* 363:918–929
26. Tsai W-C, Wu H-Y, Peng Y-S, Yang J-Y, Chen H-Y, Chiu Y-L, Hsu S-P, Ko M-J, Pai M-F, Tu Y-K (2017) Association of intensive blood pressure control and kidney disease progression in nondiabetic patients with chronic kidney disease: a systematic review and meta-analysis. *JAMA Intern Med* 177:792–799
27. Klahr S, Levey AS, Beck GJ, Caggiula AW, Hunsicker L, Kusek JW, Striker G (1994) The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. *N Engl J Med* 330:877–884
28. SPRINT Research Group (2015) A randomized trial of intensive versus standard blood-pressure control. *N Engl J Med* 373:2103–2116
29. Lee H, Yano Y, Cho SMJ, Park JH, Park S, Lloyd-Jones DM, Kim HC (2020) Cardiovascular risk of isolated systolic or diastolic hypertension in young adults. *Circulation* 141:1778–1786
30. Kula AJ, Bansal N, Prince DK, Flynn JT (2020) Blood pressure in young adults with CKD and associations with cardiovascular events and CKD progression [Abstract]. *Am Soc Nephrol Kidney Week*. Available at <https://www.asn-online.org/>
31. Gray L, Lee I-M, Sesso HD, Batty GD (2011) Blood pressure in early adulthood, hypertension in middle age, and future cardiovascular disease mortality: HAHS (Harvard Alumni Health Study). *J Am Coll Cardiol* 58:2396–2403
32. Franks PW, Hanson RL, Knowler WC, Sievers ML, Bennett PH, Looker HC (2010) Childhood obesity, other cardiovascular risk factors, and premature death. *N Engl J Med* 362:485–493
33. Sundström J, Neovius M, Tynelius P, Rasmussen F (2011) Association of blood pressure in late adolescence with subsequent mortality: cohort study of Swedish male conscripts. *BMJ* 342: d643. <https://doi.org/10.1136/bmj.d643>
34. Elliott WJ, Meyer PM (2007) Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis. *Lancet* 369:201–207
35. Verdecchia P, Reboldi G, Angeli F, Borgioni C, Gattobigio R, Filippucci L, Norgiolini S, Bracco C, Porcellati C (2004) Adverse prognostic significance of new diabetes in treated hypertensive subjects. *Hypertension* 43:963–969
36. Shen L, Shah BR, Reyes EM, Thomas L, Wojdyla D, Diem P, Leiter LA, Charbonnel B, Mareev V, Horton ES (2013) Role of diuretics, β blockers, and statins in increasing the risk of diabetes in patients with impaired glucose tolerance: reanalysis of data from the NAVIGATOR study. *BMJ* 347:f6745
37. Barzilay JI, Davis BR, Pressel SL, Cutler JA, Einhorn PT, Black HR, Cushman WC, Ford CE, Margolis KL, Moloo J (2012) Long-term effects of incident diabetes mellitus on cardiovascular outcomes in people treated for hypertension: the ALLHAT Diabetes Extension Study. *Circ Cardiovasc Qual Outcomes* 5:153–162
38. Bangalore S, Parkar S, Grossman E, Messerli FH (2007) A meta-analysis of 94,492 patients with hypertension treated with beta blockers to determine the risk of new-onset diabetes mellitus. *Am J Cardiol* 100:1254–1262
39. DiNicolantonio JJ, Fares H, Niazi AK, Chatterjee S, D'Ascenzo F, Cerrato E, Biondi-Zoccai G, Lavie CJ, Bell DS, O'Keefe JH (2015) β -Blockers in hypertension, diabetes, heart failure and acute myocardial infarction: a review of the literature. *Open Heart* 2:e000230
40. Rizos CV, Elisaf MS (2014) Antihypertensive drugs and glucose metabolism. *World J Cardiol* 6:517
41. Lurbe E, Agabiti-Rosei E, Cruickshank JK, Dominiczak A, Erdine S, Hirth A, Invitti C, Litwin M, Mancia G, Pall D (2016) 2016 European Society of Hypertension guidelines for the management of high blood pressure in children and adolescents. *J Hypertens* 34: 1887–1920
42. Gidding SS, Whelton PK, Carey RM, Flynn J, Kaelber DC, Baker-Smith C (2019) Aligning adult and pediatric blood pressure guidelines. *Hypertension* 73:938–943

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.